WallStSmart

EyePoint, Inc (EYPT)vsModerna Inc (MRNA)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Moderna Inc generates 79814% more annual revenue ($2.23B vs $2.79M). EYPT leads profitability with a 0.0% profit margin vs -141.4%. EYPT earns a higher WallStSmart Score of 24/100 (F).

EYPT

Avoid

24

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -2.13

MRNA

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 7.5
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for EYPT.

MRNAUndervalued (+69.9%)

Margin of Safety

+69.9%

Fair Value

$134.71

Current Price

$214.16

$79.45 discount

UndervaluedFair: $134.71Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EYPT2 strengths · Avg: 9.5/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

MRNA2 strengths · Avg: 9.0/10
Market CapQuality
$87.04B9/10

Large-cap with strong market position

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Areas to Watch

EYPT4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$250.69M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

MRNA4 concerns · Avg: 3.3/10
Price/BookValuation
12.6x4/10

Trading at 12.6x book value

Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-46.6%2/10

ROE of -46.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : EYPT

The strongest argument for EYPT centers on Price/Book, Debt/Equity.

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Debt/Equity.

Bear Case : EYPT

The primary concerns for EYPT are EPS Growth, Market Cap, Profit Margin.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

EYPT profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.

EYPT carries more volatility with a beta of 1.68 — expect wider price swings.

MRNA is growing revenue faster at 2.1% — sustainability is the question.

EYPT generates stronger free cash flow (-64M), providing more financial flexibility.

Bottom Line

EYPT scores higher overall (24/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

EyePoint, Inc

HEALTHCARE · BIOTECHNOLOGY · USA

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company is headquartered in Watertown, Massachusetts.

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?